Less extensive surgery after immunotherapy for advanced head and neck cancer
Part of Cancer clinical trials.
This trial compares a less extensive surgery to the standard surgery for patients with advanced head and neck cancer who have responded well to initial chemotherapy and immunotherapy. The goal is to see if a smaller operation can be just as effective while causing fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IVa head and neck squamous cell carcinoma.
- You have already received a combination of immunotherapy (PD-1 inhibitor) and chemotherapy (nab-paclitaxel with carboplatin or cisplatin), and your tumor shrank or disappeared.
- You are between 18 and 75 years old.
- Your blood counts, liver and kidney function, and other lab tests are within safe ranges before surgery.
- You have no other active cancers or serious medical conditions that would make surgery risky.
- If you can have children, you agree to use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an immunotherapy drug (similar to Keytruda) given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
This trial tests whether giving radiation therapy after surgery, adjusted based on how the cancer responds, can improve outcomes for people with advanced head and neck cancer. It may help reduce side effects while keeping the treatment effective.
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
This trial looks at whether patients with head and neck squamous cell carcinoma who had a good response to chemotherapy and immunotherapy before surgery can safely have less radiation after surgery. It aims to reduce side effects while keeping treatment effective.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.